The impact of a natural supplement (Kepar; Rikrea, Italy), containing several plant extracts such as curcuma longa, silymarin, guggul, chlorogenic acid, and inulin, was evaluated in 78 patients with metabolic syndrome (MetS; 45 men; age: 62 ± 9 years). Kepar at a dose of 2 pills/d was given for 4 months as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study. Anthropometric variables, plasma lipids, glucose parameters, and oxidative stress were measured at baseline and after 4 months. We found significant reductions in body weight (from 81.1 ± 13.5 to 79.4 ± 12.5 kg, P < .0001), body mass index (from 29.6 [23.7] to 29.3 [21.9] kg/m2, P = .001), and waist circumference (from 105 ± 11 to 102 ± 10 cm, P = .0004) as well as in fasting glucose (from 6.5 [11.7] to 6.4 [7.6] mmol/L, P = .014) and total cholesterol (from 4.8 ± 1.4 to 4.5 ± 1.0 mmol/L, P = .03). No significant changes were found in the other appraised parameters, including oxidative stress. In conclusion, after few months of treatment Kepar seems to exert beneficial effects in patients with MetS. Larger studies with a longer follow-up period are needed to confirm these preliminary findings.
Beltran-SanchezHHarhayMOHarhayMMMcElligottS. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013;62(8):697–703.
3.
ShenJGoyalASperlingL. The emerging epidemic of obesity, diabetes, and the metabolic syndrome in china. Cardiol Res Pract. 2012;2012:178675.
4.
PattiAMKatsikiNNikolicDAl-RasadiKRizzoM. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of Chitosan. Angiology. 2015;66(5):416–421.
5.
LoprinziPDMahoneySE. Association between flavonoid-rich fruit and vegetable consumption and total serum. Angiology. 2015;66(3):286–290.
6.
PapathanasopoulosACamilleriM. Dietary fiber supplements: effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology. 2010;138(1):65–72. e1–e2.
7.
AnderssonUBergerKHogbergALandin-OlssonMHolmC. Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons. Eur J Clin Nutr. 2012;66(5):585–590.
8.
RuscicaMGomaraschiMMombelliG. Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol. 2014;8(1):61–68.
9.
SkrozaNProiettiIBernardiniN. Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFalpha treatment. G Ital Dermatol Venereol. 2013;148(6):661–665.
10.
GotsisEAnagnostisPMariolisAVlachouAKatsikiNKaragiannisA. Health benefits of the mediterranean diet: an update of research over the last 5 years. Angiology. 2015;66(4):304–318.
11.
SahebkarA. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?Biofactors. 2013;39(2):197–208.
12.
FraschiniFDemartiniGEspostiD. Pharmacology of Silymarin. Clin Drug Invest. 2002;22(1):1–7.
13.
NohrLARasmussenLBStraandJ. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complement Ther Med. 2009;17(1):16–22.
14.
UlbrichtCBaschESzaparyP. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005;13(4):279–290.
15.
SzaparyPOWolfeMLBloedonLT. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290(6):765–772.
16.
MubarakAHodgsonJMConsidineMJCroftKDMatthewsVB. Supplementation of a high-fat diet with chlorogenic acid is associated with insulin resistance and hepatic lipid accumulation in mice. J Agric Food Chem. 2013;61(18):4371–4378.
17.
Rodriguez de SotilloDVHadleyM. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem. 2002;13(12):717–726.
18.
EllegardLAnderssonHBosaeusI. Inulin and oligofructose do not influence the absorption of cholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, or bile acids but increases energy excretion in ileostomy subjects. Eur J Clin Nutr. 1997;51(1):1–5.
19.
GrundySM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol. 2005;25(11):2243–2244.
20.
AllainCCPoonLSChanCSRichmondWFuPC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–475.
21.
NageleUHageleEOSauerG. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem. 1984;22(2):165–174.
22.
WarnickGRNguyenTAlbersAA. Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem. 1985;31(2):217–222.
23.
SimonPW. Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Meth Enzymol. 1994;233:182–189.
24.
HuML. Measurement of protein thiol groups and glutathione in plasma. Meth Enzymol. 1994;233:380–385. doi: 10.1016/S0076-6879(94)33021-2.
25.
PremilaMS. Ayurvedic Herbs: A Clinical Guide to the Healing Plants of Traditional Indian Medicine. Binghamton, NY: The Haworth Press, Inc.; 2006:13904–1580.
26.
ChoASJeonSMKimMJ. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48(3):937–943.
27.
ShimodaHSekiEAitaniM. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006;6:9.
28.
AgarwalRCSinghSPSaranRK. Clinical trial of gugulipid--a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626–634.
29.
NityanandSSrivastavaJSAsthanaOP. Clinical trials with gugulipid. A new hypolipidaemic agent. J Assoc Physicians India. 1989;37(5):323–328.
30.
SinghRBNiazMAGhoshS. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther. 1994;8(4):659–664.
31.
MalhotraSCAhujaMMSundaramKR. Long term clinical studies on the hypolipidaemic effect of Commiphora mukul (Guggulu) and clofibrate. Indian J Med Res. 1977;65(3):390–395.
32.
WangXGreilbergerJLedinskiGKagerGPaigenBJurgensG. The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL. Atherosclerosis. 2004;172(2):239–246.
33.
VinsonJABurnhamBRNagendranMV. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012;5:21–27.
34.
ObohGAgunloyeOMAdefeghaSAAkinyemiAJAdemiluyiAO. Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): a comparative study. J Basic Clin Physiol Pharmacol. 2015;26(2):165–170.
35.
TunnicliffeJMEllerLKReimerRAHittelDSShearerJ. Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats. Appl Physiol Nutr Metab. 2011;36(5):650–659.
36.
KaurGCM. Amelioration of obesity, glucose intolerance, and oxidative stress in high-fat diet and low-dose streptozotocin-induced diabetic rats by combination consisting of “curcumin with piperine and quercetin”. ISRN Pharmacol. 2012;2012:957283.
37.
AzizMTEl IbrashyINMikhailidisDP. Signaling mechanisms of a water soluble curcumin derivative in experimental type 1 diabetes with cardiomyopathy. Diabetol Metab Syndr. 2013;5(1):13.
38.
HuseiniHFLarijaniBHeshmatR. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 2006;20(12):1036–1039.
39.
Di PierroFVillanovaNAgostiniFMarzocchiRSoveriniVMarchesiniG. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes. 2012;5:213–217.
40.
Di PierroFPutignanoPVillanovaNMontesiLMoscatielloSMarchesiniG. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167–174.
41.
RussoFRiezzoGChiloiroM. Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr Pharm Des. 2010;16(7):825–831.
42.
SugataniJOsabeMWadaT. Comparison of enzymatically synthesized inulin, resistant maltodextrin and clofibrate effects on biomarkers of metabolic disease in rats fed a high-fat and high-sucrose (cafeteria) diet. Eur J Nutr. 2008;47(4):192–200.
43.
OsawaTKatoY. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann N Y Acad Sci. 2005;1043:440–451.
44.
KiruthigaPVPandianSKDeviKP. Silymarin protects PBMC against B(a)P induced toxicity by replenishing redox status and modulating glutathione metabolizing enzymes--an in vitro study. Toxicol Appl Pharmacol. 2010;247(2):116–128.
45.
BouderbaSSanchez-MartinCVillanuevaGRDetailleDKoceirEA. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes. J Diabetes. 2014;6(2):184–192.
46.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol. 2011;9(5):531–532.
47.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
48.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
